Palatin Posts $17.3M Loss, Faces Going Concern Doubt Amid Pipeline Progress

TL;DR

**PTN is a high-risk bet on early-stage MCR pipeline assets, but the 'going concern' warning and delisting make it a speculative gamble for traders.**

AI Summary

PALATIN TECHNOLOGIES INC reported a net loss of $17.3 million for the fiscal year ended June 30, 2025, and management has expressed substantial doubt about the company's ability to continue as a going concern. The company's strategy focuses on developing first-in-class medicines modulating the melanocortin receptor (MCR) system, particularly MC4R agonists for obesity and MC1R agonists for inflammatory and autoimmune diseases. Key developments include positive topline Phase 2 data for co-administration of bremelanotide with tirzepatide for obesity in Q1 2025, and positive topline Phase 2 data for PL8177 for ulcerative colitis in Q1 2025. PALATIN also successfully completed a Phase 3 clinical trial for PL9643 for dry eye disease. In August 2025, Boehringer Ingelheim acquired certain patent applications for retinal disease treatments, while Cosette Pharmaceuticals, Inc. acquired Vyleesi in December 2023, with future milestone payments expected to partially fund development. The company projects IND filings for a novel once-weekly MC4R peptide agonist and an oral small molecule MC4R agonist (PL7737) in Q1 2026.

Why It Matters

Palatin's substantial net loss of $17.3 million and the 'going concern' warning signal significant financial instability, raising red flags for investors about long-term viability and potential dilution. Despite these financial challenges, the company's pipeline, particularly positive Phase 2 data for obesity and ulcerative colitis treatments, and a completed Phase 3 for dry eye disease, offers a glimmer of hope for future revenue streams through strategic partnerships. However, the delisting from NYSE American to OTCQB in May 2025 highlights a severe loss of market confidence and liquidity, making it harder for investors to trade shares and for the company to raise capital. The competitive landscape in obesity and inflammatory diseases is fierce, and Palatin's ability to secure strong partners like Boehringer Ingelheim and Cosette will be crucial for commercializing its MCR-targeted therapies.

Risk Assessment

Risk Level: high — PALATIN TECHNOLOGIES INC has a history of substantial net losses, including a net loss of $17.3 million for the year ended June 30, 2025, and management has determined there is 'substantial doubt' regarding its ability to continue as a going concern. Furthermore, the company's common stock was delisted from the NYSE American on May 7, 2025, due to low selling price, and now trades on the OTCQB Venture Market under 'PTNT', significantly reducing liquidity and investor access.

Analyst Insight

Investors should approach PTN with extreme caution due to the 'going concern' warning and delisting. Only highly speculative investors with a high-risk tolerance should consider a position, focusing on the potential for significant milestone payments from Cosette and Boehringer Ingelheim, and the successful advancement of its MC4R and MC1R agonist pipeline through partnerships.

Key Numbers

• $17.3 million — Net Loss (for the fiscal year ended June 30, 2025, indicating substantial operating losses.)
• $25,548,549 — Aggregate Market Value (of voting and non-voting common equity held by non-affiliates as of December 31, 2024, reflecting a low market capitalization.)
• 973,291 — Shares Outstanding (as of September 19, 2025, indicating the total number of common shares.)
• 838,142 — Shares Underlying Convertible Securities (as of September 19, 2025, representing potential future dilution for stockholders.)
• May 7, 2025 — Delisting Date (when trading of common stock was suspended on NYSE American due to low selling price.)
• December 2023 — Vyleesi Acquisition Date (when Cosette Pharmaceuticals, Inc. acquired Vyleesi, a key asset for future milestone payments.)
• August 2025 — Boehringer Ingelheim Agreement Date (when Boehringer Ingelheim acquired certain patent applications for retinal diseases.)
• Q1 2025 — Positive Phase 2 Data (reported for co-administration of bremelanotide with tirzepatide for obesity and for PL8177 for ulcerative colitis.)
• Q1 2026 — Projected IND Filing (for a novel once-weekly MC4R peptide agonist and PL7737, an oral small molecule MC4R agonist.)

Key Players & Entities

• PALATIN TECHNOLOGIES INC (company) — registrant
• Boehringer Ingelheim International GmbH (company) — acquirer of patent applications
• Cosette Pharmaceuticals, Inc. (company) — acquirer of Vyleesi product
• NYSE American LLC (regulator) — exchange that delisted PTN
• Vyleesi (company) — FDA-approved product acquired by Cosette
• PL9643 (company) — MCR agonist for dry eye disease
• PL8177 (company) — oral peptide for ulcerative colitis
• PL7737 (company) — oral small molecule MC4R agonist
• tirzepatide (company) — GLP-1 agonist co-administered with bremelanotide
• bremelanotide (company) — melanocortin agonist

FAQ

Risk Factors

• Substantial Doubt About Going Concern [high — financial]: The company reported a net loss of $17.3 million for the fiscal year ended June 30, 2025. Management has expressed substantial doubt regarding Palatin's ability to continue as a going concern due to significant operating losses since inception and the need for additional financing.
• Need for Additional Financing [high — financial]: Palatin's ability to continue operations is contingent upon obtaining additional financing. There is uncertainty regarding the availability of funds or delays in receiving them, which could adversely affect business operations.
• Clinical Trial and Regulatory Delays [medium — regulatory]: Increases in costs and delays in conducting human clinical trials, as well as the performance of contractors and suppliers, could adversely affect the company's business, financial condition, and results of operations. Regulatory submissions are also subject to timing and approval.
• Commercialization Risk of Acquired Assets [medium — market]: The success of products acquired by third parties, such as Vyleesi by Cosette Pharmaceuticals, Inc. and patent applications by Boehringer Ingelheim, is uncertain. Milestone payments are contingent on Cosette achieving sufficient sales for Vyleesi, and Boehringer Ingelheim's ability to successfully develop products for retinal diseases is not guaranteed.
• Delisting from NYSE American [medium — market]: Trading of Palatin's common stock was suspended on NYSE American on May 7, 2025, due to a low selling price. This delisting impacts liquidity and investor perception.
• Dependence on Third-Party Contractors [medium — operational]: The company relies on contractors and suppliers for clinical trial conduct and product development. Reductions in productivity or supply chain constraints from these third parties can negatively impact operations.

Industry Context

Palatin operates in the biopharmaceutical industry, focusing on novel therapeutics for significant unmet medical needs. The company's strategy leverages the melanocortin receptor system, a complex biological pathway with potential applications in obesity, inflammation, and autoimmune diseases. The competitive landscape includes large pharmaceutical companies and smaller biotech firms also developing treatments for these conditions, often through partnerships and collaborations.

Regulatory Implications

Palatin faces significant regulatory hurdles inherent in drug development. Successful progression through clinical trials (Phase 2, Phase 3) and subsequent IND filings are critical. Delays or failures in these stages, or issues with manufacturing and quality control, can impede market entry and commercialization. The company's ability to secure regulatory approval for its pipeline candidates is paramount to its future success.

What Investors Should Do

1. Monitor financing activities closely.
2. Track progress of Phase 3 trials and IND filings.
3. Evaluate milestone payment potential from Vyleesi and Boehringer Ingelheim.
4. Assess the impact of delisting from NYSE American.

Key Dates

• 2025-06-30: Fiscal Year End — Reported a net loss of $17.3 million for the fiscal year.
• 2025-08-01: Boehringer Ingelheim Acquisition of Patent Applications — Boehringer Ingelheim acquired certain patent applications for retinal disease treatments, providing potential future revenue streams through milestones, though development success is not guaranteed.
• 2025-05-07: Delisting from NYSE American — Trading of common stock was suspended due to low selling price, impacting liquidity and investor confidence.
• 2025-01-01: Q1 2025 Positive Phase 2 Data — Reported positive topline Phase 2 data for co-administration of bremelanotide with tirzepatide for obesity and for PL8177 for ulcerative colitis, advancing key pipeline candidates.
• 2023-12-01: Vyleesi Acquisition by Cosette Pharmaceuticals — Cosette Pharmaceuticals acquired Vyleesi, with Palatin expecting future milestone payments which are crucial for funding development.
• 2026-01-01: Projected IND Filings — Anticipates IND filings for a novel once-weekly MC4R peptide agonist and PL7737 (oral small molecule MC4R agonist), indicating progress in early-stage development.

Glossary

Melanocortin Receptor (MCR) System

A system of receptors in the body that plays a role in various physiological processes including inflammation, immune response, metabolism, and sexual function. (Palatin's core strategy revolves around developing drugs that modulate this system, targeting specific receptors like MC4R and MC1R.)

MC4R Agonists

Molecules that activate the Melanocortin 4 Receptor, primarily being developed by Palatin for obesity and metabolic disorders. (This is a key focus area for Palatin's product development, with candidates like bremelanotide and PL7737.)

MC1R Agonists

Molecules that activate the Melanocortin 1 Receptor, being developed by Palatin for inflammatory and autoimmune diseases. (Represents another significant therapeutic area for Palatin, with PL8177 for ulcerative colitis and PL9643 for dry eye disease.)

Going Concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. A 'substantial doubt' means there is significant uncertainty about this ability. (Management has expressed substantial doubt about Palatin's ability to continue as a going concern, highlighting severe financial distress.)

IND Filing

Investigational New Drug application, submitted to regulatory authorities (like the FDA) to seek permission to start clinical trials in humans. (Projected IND filings for new drug candidates in Q1 2026 signal progression in the drug development pipeline.)

GLP-1 Agonist

Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic the effects of the GLP-1 hormone, often used for type 2 diabetes and weight management. (Palatin is exploring co-administration of its MCR agonists with GLP-1 agonists like tirzepatide for obesity, indicating a strategy to combine therapies.)

Topline Data

The primary, most important results from a clinical trial, usually announced before detailed analysis. (Positive topline data from Phase 2 trials for obesity and ulcerative colitis are key positive developments for Palatin's pipeline.)

Year-Over-Year Comparison

The fiscal year ended June 30, 2025, saw Palatin report a significant net loss of $17.3 million, underscoring continued operating losses. While specific revenue figures for the current year are not detailed in the provided context, the company's reliance on future milestone payments and the absence of product sales suggest a lack of substantial revenue generation. The delisting from NYSE American on May 7, 2025, indicates a worsening financial situation compared to the previous year, likely driven by a sustained low stock price and concerns about financial stability.

Key Financial Figures

• $17.3 million — ial net losses, including a net loss of $17.3 million for the year ended June 30, 2025, and e

Filing Documents

• ptn_10k.htm (10-K) — 1765KB
• ptn_ex1027.htm (EX-10.27) — 116KB
• ptn_ex1028.htm (EX-10.28) — 115KB
• ptn_ex21.htm (EX-21) — 2KB
• ptn_ex23.htm (EX-23) — 2KB
• ptn_ex311.htm (EX-31.1) — 9KB
• ptn_ex312.htm (EX-31.2) — 9KB
• ptn_ex321.htm (EX-32.1) — 2KB
• ptn_ex322.htm (EX-32.2) — 3KB
• ptn_ex1040img2.jpg (GRAPHIC) — 4KB
• ptn_10kimg27.jpg (GRAPHIC) — 51KB
• ptn_10kimg26.jpg (GRAPHIC) — 4KB
• ptn_ex1039img4.jpg (GRAPHIC) — 4KB
• 0001654954-25-011030.txt ( ) — 6351KB
• ptn-20250630.xsd (EX-101.SCH) — 66KB
• ptn-20250630_lab.xml (EX-101.LAB) — 325KB
• ptn-20250630_cal.xml (EX-101.CAL) — 53KB
• ptn-20250630_pre.xml (EX-101.PRE) — 252KB
• ptn-20250630_def.xml (EX-101.DEF) — 116KB
• ptn_10k_htm.xml (XML) — 761KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 13 Item 1B. Unresolved Staff Comments 36 Item 1C. Cybersecurity 36 Item 2.

Properties

Properties 36 Item 3.

Legal Proceedings

Legal Proceedings 37 Item 4. Mine Safety Disclosures 37 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 38 Item 6. [Reserved] 38 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 43 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 66 Item 9A.

Controls and Procedures

Controls and Procedures 66 Item 9B. Other Information 66 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 66 PART III Item 10. Directors, Executive Officers and Corporate Governance 67 Item 11.

Executive Compensation

Executive Compensation 71 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 79 Item 13. Certain Relationships and Related Transactions, and Director Independence 82 Item 14. Principal Accountant Fees and Services 82 PART IV Item 15. Exhibits and Financial Statement Schedules 84 Item 16. Form 10-K Summary 89 Table of Contents Special Note Regarding Forward-Looking Statements In this Annual Report on Form 10-K (this "Annual Report") references to "we," "our," "us," the "Company" or "Palatin" means Palatin Technologies, Inc. and its subsidiary. our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern; our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability; our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our producti

Business

Item 1. Business. Our Business Overview Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor ("MCR") system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. We believe that our MC1R agonist peptides have broad anti-inflammatory effects and utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. We are also developing peptides that are active at more than one melanocortin receptor and small molecule MCR agonists. Our product development activities focus primarily on use of MC4R agonists for treatment of obesity. The Company is developing MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. We are also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1R agonist peptides in development have broad anti-inflammatory effects and appear to utilize

View Full Filing

View this 10-K filing on SEC EDGAR